Benefits of a laser chorioretinal anastomosis plus ranibizumab vs ranibizumab alone for central retinal vein occlusion: 4-year results.

Evaluate what clinical gains can be achieved over conventional treatment with ranibizumab alone for central retinal vein occlusion (CRVO) when causal pathology is additionally successfully addressed with a laser-induced chorio-retinal anastomosis (L-CRA).

Source: American Journal of Ophthalmology - April 6, 2023 Category: Opthalmology Authors: Ian L McAllister, Lynne A Smithies, Fred K Chen, David A Mackey, Paul G Sanfilippo Source Type: research